Dr. Sznol on Managing Toxicities in Treatment of Melanoma

Mario Sznol, MD
Published: Wednesday, Apr 15, 2015



Mario Sznol, MD, professor of medicine (medical oncology), clinical research program leader, Melanoma Program, Yale Cancer Center, discusses how to manage toxicities in treatment of melanoma.

Toxicities from chemotherapy tend to be more severe than those from immunotherapy, Sznol explains. Oncologists are capable of managing both toxicities, but they are two different categories and should be handled as such.

Oncologists need to be in close contact with patients who are experiencing adverse events. When they see an immune-based toxicity, it is imperative they know when to administer steroids to patients, as well as knowing the appropriate dosage and duration. Patients may also require beyond a steroid to a second immune suppressive agent.

Immune suppressive agents should not be given to patients with mild, reversible auto-immune toxicities such as rashes. However, if patients have grade 3 diarrhea, for example, they should be administered high-dose steroids immediately.

SELECTED
LANGUAGE


Mario Sznol, MD, professor of medicine (medical oncology), clinical research program leader, Melanoma Program, Yale Cancer Center, discusses how to manage toxicities in treatment of melanoma.

Toxicities from chemotherapy tend to be more severe than those from immunotherapy, Sznol explains. Oncologists are capable of managing both toxicities, but they are two different categories and should be handled as such.

Oncologists need to be in close contact with patients who are experiencing adverse events. When they see an immune-based toxicity, it is imperative they know when to administer steroids to patients, as well as knowing the appropriate dosage and duration. Patients may also require beyond a steroid to a second immune suppressive agent.

Immune suppressive agents should not be given to patients with mild, reversible auto-immune toxicities such as rashes. However, if patients have grade 3 diarrhea, for example, they should be administered high-dose steroids immediately.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x